Despite significant advances in the treatment of acute myeloid leukemia (AML), the majority of patients will succumb to drugresistant AML. To overcome this resistance, we have developed a novel fusion toxin consisting of the catalytic and translocation subunits of diphtheria toxin (DT 388 ) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF). In vitro, DT 388 -GM-CSF demonstrated significant activity against numerous AML cell lines and fresh AML blasts. To determine its in vivo efficacy, we developed an in vivo model of human AML in severe combined immunodeficiency (SCID) mice injected intravenously with 1 × 10 7 HL-60 cells (AML-M2 cell line). The SCID mice developed abdominal masses, infiltration of the liver and bone marrow, and peripheral blasts with a median survival of 42.5 days. We tested DT 388 -GM-CSF, ara-C, human GM-CSF, and DAB 389 IL-2, which were injected intraperitoneally on days 2-6 in this model. DT 388 -GM-CSF significantly improved survival of the SCID mice over Ara-C, DAB 389 IL-2, or control (P Ͻ 0.001). DT 388 -GM-CSF-treated mice who developed leukemia exhibited no difference in the number of GM-CSF receptors (P = 0.39), ligand affinity (P = 0.77), or sensitivity (P = 0.56) to DT 388 -GM-CSF as compared to the controls. Frank leukemia in DT 388 -GM-CSF-treated mice may be due to incomplete penetration of drug into tissues rather than cellular resistance. DT 388 -GM-CSF is an active therapeutic agent in our SCID mouse model of AML with a unique mechanism of action and differing toxicities than current cytotoxic agents.
Introduction
Acute myeloid leukemia (AML) is the most common type of leukemia with 9400 new cases expected to be diagnosed in 1998. 1 In a recent study of 1088 evaluable patients with newly diagnosed AML who received standard induction with daunorubicin and cytarabine, the likelihood of survival at 4 years was 38%, 27%, and 9% for patients less than 40 years old, between 40-60 years old, and greater than 60 years old, respectively. 2 In select patients, an allogeneic bone marrow transplantation offers a 59% survival rate at 4 years, but elderly patients are excluded from receiving an allogeneic bone marrow transplantation. 3 Despite recent advances in understanding the biology of AML and its treatment, new treatment strategies are needed for the treatment of AML, especially in the elderly population.
One novel modality for the treatment of AML is fusion toxins, composed of protein synthesis-inactivating peptide toxins covalently linked to AML-selective peptide ligands. Currently, Correspondence we are developing a novel fusion toxin consisting of the catalytic and translocation subunits of diphtheria toxin (DT 388 ) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF). The granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor is present on the majority of AML blasts. 4 Our group, as well as others, have found modified diphtheria toxin linked to human GM-CSF to be active against various AML cell lines, including HL-60 cells. [5] [6] [7] We subsequently tested fresh AML blasts from 50 patients with untreated AML for the presence of the high-affinity GM-CSF receptor and found that 44/50 (88%) expressed у35 highaffinity receptors per cell. 8 In a colony formation assay, 30/50 AML samples developed colonies of Ͼ20 cells, and DT 388 -GM-CSF reduced AML colony formation by at least 50% in 27/30 samples (90%). In the samples where DT 388 -GM-CSF had no effect, two of the AML blasts had Ͻ35 GM-CSF receptors. In addition, DT 388 -GM-CSF demonstrated only modest toxicity to normal bone marrow progenitors. 8 Terpstra and colleagues 9 found that DT 388 -GM-CSF eliminated the AML cells with long-term repopulating abilities in vivo, whereas normal hematopoietic progenitors were spared. In C57BL/6 mice, we determined the maximum tolerated dose (MTD) of DT 388 -GM-CSF to be 84.4 g/kg/day when administered for 5 consecutive days intraperitoneally. The dose-limiting toxicity in mice is acute proximal tubular necrosis in the kidney. 10 To test the in vivo activity of DT 388 -GM-CSF, we developed a severe combined immunodeficient (SCID) mouse model for AML utilizing a cytokine-independent cell line, HL-60 (a human AML-M2 cell line). The SCID mice were treated with the MTD of DT 388 -GM-CSF starting 1 day after the injection of 1 × 10 7 HL-60 cells. We now report the anti-leukemic efficacy of this dose and schedule of DT 388 -GM-CSF in vivo, and provide evidence that the relapsing leukemia is still sensitive to DT 388 -GM-CSF.
Materials and methods

Cells
HL-60 cells, a FAB-M2 AML cell line, were obtained from American Type Culture Collection (Rockville, MD, USA) and maintained in a suspension culture in RPMI-1640 (BioWhittaker, Walkersville, MD, USA) supplemented with 20% heat-inactivated fetal bovine serum (Hyclone Laboratories, Logan, UT, USA) and penicillin (125 units/ ml)/streptomycin (125 g/ml)/glutamine (2 mm) (BioWhittaker) in a humidified 37°C, 5% CO 2 incubator. 11 Cells were passed twice weekly and the cells were determined to be mycoplasma-free on a quarterly basis. In the CFU-L assay, the IC 50 for HL-60 cells ranges from 2-5 × 10 −12 mol/l (unpublished data) while the median IC 50 for 30 different AML patient samples was 4× 10 −12 mol/l (range, 5-Ͼ4000 × 10 −12 mol/l). 8 Because of its cytokine-independent growth and its CFU-L IC 50 comparable to the patient samples, we used HL-60 cells in our model.
Animals
C.B-17-SCID/SCID mice (females; age 4-6 weeks) were obtained from Harlan Sprague Dawley (Indianapolis, IN, USA) or Charles River (Wilmington, MA, USA) and maintained in micro-isolator cages housed in laminar flow cubicles in a positive pressure room. The temperature in the room ranged from 22-25°C. The water was autoclaved and provided ad libitum. The food was irradiated and provided ad libitum. The mice were allowed to adjust to their new environment for 1 week. The mice were then irradiated with 300 cGy total body irradiation to diminish natural killer cell activity. 12, 13 After 24 h of observation, the mice were injected i.v. via tail vein with 1 × 10 7 HL-60 cells diluted in 0.1 ml of HBSS (BioWhittaker). After completion of all injections, HL-60 cells from residual syringes were Ͼ90% viable by trypan exclusion. A total of 20 control mice were used. For treated mice, DT 388 -GM-CSF (n = 15), ara-C (n = 11) (Schein, Florham Park, NJ, USA), human GM-CSF (n = 10) (Immunex, Seattle, WA, USA), and DAB 389 IL-2 (n = 8) (Seragen, Boston, MA, USA) were injected intraperitoneally (i.p.) at a dose of 84 g/kg/day, 4 mg/kg/day, 1.0 g/day, and 84 g/kg/day, respectively, on days 2-6. The mice were examined daily for overall activity and for the presence of masses. Moribund mice were sacrificed.
Flow cytometry
Blood from normal and leukemia-bearing mice was diluted 20-fold with PBS containing 0.2% bovine serum albumin and 0.01% sodium azide (PBA) and centrifuged at 600 g for 7 min. Twenty volumes of Ortholyse (Ortho Biotech, Raritan, NJ, USA) was added and incubated at room temperature for 10 min. Cells were then centrifuged for three minutes at 600 g and washed twice with 20 volumes of PBA and resuspended in 0.5 ml of mouse serum (Sigma-Aldrich, St, Louis, MO, USA) for 10 min. Cells were then washed with PBA and resus- 
Autopsies
Moribund SCID mice were sacrificed painlessly by standard CO 2 asphyxiation, consistent with the recommendations of the Panel on Euthanasia of the American Veterinary Medical Association. Initially, samples from the lungs, thymus, heart, esophagus, trachea, lymph node, liver, spleen, pancreas, kidneys, adrenals, gallbladder, stomach, duodenum, jejunum, colon, ovaries, uterus, brain, spinal cord, muscle, sternum, femur and abdominal mass were removed. After development of the model, only the lungs, heart, liver, spleen, kidneys, brain, sternum, femur and abdominal mass were removed. The tissues were fixed in 4% buffered formaldehyde and 631 embedded in paraffin. Sections were stained with hematoxylin and eosin and examined under the microscope.
For four mice in both the control and DT 388 -GM-CSFtreated arms at autopsy, abdominal masses were resected, minced, separated by sedimentation using Ficoll-Hypaque (Organon Teknika, Durham, NC, USA), and tested for the number of high-affinity GM-CSF receptors, dissociation constant, and the protein synthesis IC 50 for the HL-60 cells from resected masses as previously described.
5,8
Statistical analysis
Survival was analyzed by the Kaplan-Meier method with the Mantel-Cox (Logrank) test for comparison of survival between the groups. The data from the six mice in the DT 388 -GM-CSFtreated arm surviving Ͼ150 days was censored. For comparison of the number of GM-CSF receptors, dissociation constant, and IC 50 , a Mann-Whitney test was utilized.
Results
The median survival of the 20 control mice injected i.v. with 1 × 10 7 HL-60 cells was 42.5 days with a range of 28-67 days (Figure 1 ). The SCID mice developed abdominal masses, infiltration of the liver, kidney, muscle, lung, spleen, and bone marrow (Figure 2 ). Four out of five moribund mice exhibited peripheral blasts, detected by an anti-human CD33 antibody using flow cytometry (Figures 3 and 4) . Two mice tested on day 2 did not demonstrate any circulating peripheral blasts (data not shown).
DT 388 -GM-CSF significantly improved survival of the SCID mice over ara-C, DAB 389 IL-2, and control (P Ͻ 0.001) ( Figure  1 ). SCID mice treated with DT 388 -GM-CSF, ARA-C, GM-CSF, or DAB 389 -IL-2 survived a median (range) of 83 days (20-Ͼ150), 38 days (7-45), 34.5 days (32-40), or 37 days (34-
Figure 3
Peripheral blood blasts in SCID mice detected by flow cytometry using anti-CD33 PE. A, control mouse; B, control mouse blood + 5 × 10 6 HL-60 cells; C, SCID 3; and D, SCID 4.
Figure 4
The percent of cells circulating in peripheral blood positive for human CD33. 43), respectively. Two mice treated with DT 388 -GM-CSF with died on day 20 with no visible abdominal masses. When found, their organs were also autolysed for autopsy. We presumed that they died from toxicity of the DT 388 -GM-CSF because the timeframe is consistent with our prior toxicology study. 10 The six mice surviving Ͼ150 days were sacrificed, and their autopsies revealed no gross evidence of tumor, but three out of the six showed microscopic evidence of residual tumor. One of the three exhibited bone marrow involvement (femur and sternum) and soft tissue involvement (kidney, liver, and pericardium). The other two exhibited only soft tissue involvement (lung (n = 1) and abdominal mass (n = 2)). One mouse treated with ara-C died on day 7 secondary to an aplastic marrow, a hypocellular spleen, and pulmonary congestion.
We resected the abdominal masses from four controls and
Figure 5
The number of high-affinity GM-CSF receptors/cell (HL-60) from control and DT 388 -GM-CSF-treated mice determined by Scatchard analysis as previously described. 5, 8 (Bars indicate standard deviations.)
Figure 6
Dissociation constants (×10 −11 mol/l) for the high-affinity GM-CSF receptors on HL-60 cells from control and DT 388 -GM-CSFtreated mice determined by Scatchard analysis as previously described. 5, 8 (Bars indicate standard deviations.)
four DT 388 -GM-CSF-treated SCID mice. There was no difference in the number of high-affinity GM-CSF receptors, dissociation constant, and or sensitivity to DT 388 -GM-CSF between the treated and control mice ( Figures 5, 6 and 7).
Discussion
Our observation of in vivo anti-leukemic efficacy of DT 388 -GM-CSF extends prior in vitro results with human leukemic progenitors. In a recent report by Perentesis and colleagues, 14 4 × 10 6 HL-60 cells were injected i.p. followed by DT ct GMCSF (approximately 50 g/kg/day) i.p. × 5 days starting 24 h after inoculation of the HL-60 cells. With treatment, the median survival was prolonged from 42 to Ͼ210 days, and nearly 60% of mice disease-free at 180 days.
14 DT ct GMCSF is essentially identical to DT 388 -GM-CSF with the former molecule containing the first 385 amino acids of diphtheria toxin and the latter containing the first 388 amino acids of the diphtheria toxin. However, it could not be predicted that DT 388 -GM-CSF would produce anti-tumor activity in our model
Figure 7
The sensitivity (IC 50 ) of HL-60 cells from control and DT 388 -GM-CSF-treated mice to DT 388 -GM-CSF as previously described. 5 ), and either absent receptors or a modified EF2 diphthamide residue substrate is observed. 16, 17 In our model system, relapsed HL-60 blasts from abdominal masses retained a high expression of the high-affinity GM-CSF receptors and sensitivity to DT 388 -GM-CSF. This suggests that inadequate penetration of DT 388 -GM-CSF rather than a cellular resistance mechanism was responsible for treatment failure. Further, it indicates retreatment is an option, if an immune response to DT 388 -GM-CSF is minimal.
These results demonstrate that DT 388 -GM-CSF is an active therapeutic agent for AML with a unique mechanism of action and differing toxicities compared to current cytotoxic agents. DT 388 -GM-CSF warrants further preclinical development.
